Howmedica to license bone cement from Orthovita:
This article was originally published in Clinica
Howmedica is to license Orthovita's new bone cement technology in an exclusive worldwide agreement. The Rutherford, New Jersey-based company will work with Orthovita to complete the development of Orthocomp, which received a US patent in 1997. Orthovita, located in Malvern, Pennsylvania, is expected to submit a 510(k) for non-load bearing applications. It plans to submit an Investigational Device Exemption (IDE) for load-bearing indications and as an implant cement by the end of the year. Of the annual 650,000 worldwide joint replacement procedures, about 60% involve the use of bone cement.
You may also be interested in...
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.